In April 2025 Inspira treated its first patient using the ART100 system at Westchester Medical Center, marking the start of active clinical use. Subsequent to year-end the system was deployed at additional leading U.S. hospitals, entered formal procurement pathways at a major healthcare network, and advanced a quotation into capital intake at a leading academic center. To support this expansion the company appointed Mike Hershkovitz as Vice President of Global Sales and secured binding purchase orders totaling $49.5 million, expected to drive revenue recognition in 2026.

For the year ended December 31, 2025 Inspira recognized $289,000 in revenue from initial ART100 deployments. Research and development expenses rose to $7.496 million and general and administrative expenses increased to $5.532 million, while sales and marketing expenses decreased to $588,000. Total operating expenses were $13.623 million, resulting in a net loss of $13.22 million and cash and equivalents of $3.159 million at year-end.

Subsequent to year-end the company completed a registered direct offering generating $4.75 million in gross proceeds to support ongoing operations and commercial expansion. Inspira advanced its HYLA blood sensor into a next-generation standalone configuration and expanded its intellectual property portfolio with U.S. patent approval for the ART500 core technology extending protection through 2043. The company also terminated a proposed acquisition term sheet and continues evaluating strategic alternatives to enhance shareholder value.